close


close
SYNVISC packaging
genzyme corporationresearchgenzyme websites
Information for patientsContact Us
HomeAbout SYNVISCClinical Info and ResearchReimbursement ResourcesOrdering SYNVISCPatient Education
SYNVISC

Improved Function

When your patients experience greater pain relief, they may experience greater improvement in function, too.*

As you can see in the graph below, which shows the results of a head-to-head trial conducted by Raman et al., SYNVISC® provided a greater improvement in function than Hyalgan®—most notably at week 26. 1* These results are consistent with those of a meta-analysis by Wang et al., demonstrating that SYNVISC is unsurpassed in improving patient function. 2

SYNVISC provides greater improvement in patient function1

From a head-to-head trial of SYNVISC (hylan G-F 20) vs Hyalgan (sodium hyaluronate)

The benefits of SYNVISC

Prospective, observer-blinded, active-controlled trial of 356 patients with OA knee pain who were randomized to receive either 3 weekly injections of SYNVISC or 5 weekly injections of Hyalgan. Follow-up visits occurred at 6 weeks, 3 months, 6 months, and 1 year. Mean age of patients was 66.7 years. Most had radiographically confirmed Kellgren-Lawrence grade III OA at baseline (SYNVISC 61%; Hyalgan 59%). Functional outcomes were assessed using Oxford, Tegner, and UCLA knee scores. 1

Hyalgan is a registered trademark of Fidia S.P.A.

*Well-controlled clinical trials demonstrate that reducing pain can help improve function as measured by WOMAC pain and function domains. 3 4




Important Safety Information

SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

SYNVISC is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC in children and in pregnant or lactating women have not been established. It is unknown whether SYNVISC is excreted in human milk.

View the Complete Prescribing Information for SYNVISC (PDF, 146k)